Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXON 19 DELETION
(
ENST00000275493.7 )
EGFR EXON 19 DELETION ( ENST00000275493.7 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- 90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and exon 19 deletion of EGFR was associated with longer time to treatment failure than those with wild-type EGFR (median 8.9 versus 2.1). In multivariate analysis, exon 19 deletion was a significant predictive factor for TTF (HR = 0.0320; P < .0001).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1666
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/133
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Gefitinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 18509184
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Gefitinib | Sensitivity | true |